Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Kushen Injection versus gemcitabine after TURBT for non-muscle-invasive bladder cancer
ChiCTR1800016205Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Jun 2018
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of compound kushen injection and gemcitabine in non-muscle-invasive bladder cancer (NMIBC) (3 arms), sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoints: recurrence rate and progression rate. Started Jun 2018; status: recruiting.
02
Drugs
compound kushen injectiongemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR1800016205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016205.